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SUMMARY
Thorough psychosocial screening of donor candidates is required in order
to minimize potential negative consequences and to strive for optimal
safety within living donation programmes. We aimed to develop an evi-
dence-based tool to standardize the psychosocial screening process. Key
concepts of psychosocial screening [1] were used to structure our tool:
motivation and decision-making, personal resources, psychopathology,
social resources, ethical and legal factors and information and risk process-
ing. We (i) discussed how each item per concept could be measured, (ii)
reviewed and rated available validated tools, (iii) where necessary devel-
oped new items, (iv) assessed content validity and (v) pilot-tested the new
items. The resulting ELPAT living organ donor Psychosocial Assessment
Tool (EPAT) consists of a selection of validated questionnaires (28 items
in total), a semi-structured interview (43 questions) and a Red Flag Check-
list. We outline optimal procedures and conditions for implementing this
tool. The EPAT and user manual are available from the authors. Use of
this tool will standardize the psychosocial screening procedure ensuring
that no psychosocial issues are overlooked and ensure that comparable
selection criteria are used and facilitate generation of comparable psy-
chosocial data on living donor candidates.
Transplant International 2018; 31: 56–70
Key words
donor selection, kidney failure, liver failure, living donors, organ transplantation, psychosocial
aspects
Received: 8 February 2017; Revision requested: 20 March 2017; Accepted: 14 August 2017;
Published online: 21 September 2017





One option to alleviate the shortage of kidneys and liv-
ers for transplantation is living donation. The advan-
tages of receiving an organ from a living donor
compared to one from a deceased donor are manifold.
There is a reduction in waiting time and in the case of
pre-emptive transplantation, avoidance of dialysis,
which further minimizes the negative impact on the
recipient’s quality of life and physical condition. Due to
the extensive medical workup undertaken by living
donors, the organ is known to have come from some-
one who is healthy and free from disease. This means
that the organ is in optimal condition and, due to a
planned operation, both the warm and cold ischaemic
times are kept to a minimum. These factors all con-
tribute to superior outcomes when compared to recipi-
ents of deceased donor organs [1,2].
Over the past decades, there has been an exponential
growth in living donation programmes; kidney donation
in particular. Initially, donors and recipients were genet-
ically related, such as parents and siblings (‘specified
donors’) [3]. This has gradually expanded to include
genetically unrelated donors, such as partners and
friends (‘specified donors’), and those who donate to an
unrelated and unknown person (‘unspecified living
donors’) [4,5].
The current evidence indicates that when living
donors are appropriately screened and selected, long-
term physical and psychological morbidity is limited,
and there is no impact on life span [6–14]. Recent stud-
ies in living kidney donors have shown that there may
be a small increased relative risk of end-stage renal fail-
ure when compared to matched healthy nondonors,
however, the absolute risk remains low [15,16]. Living
liver donation is a more risky procedure for the donor
than living kidney donation [17]. However, health-
related quality of life has been shown to recover to
baseline after liver donation and be higher than general
population norm scores [18], as is the case with kidney
donors [9]. Furthermore, among liver and kidney
donors, interpersonal relationships appear to remain the
same or improve after donation [7] and the majority of
donors do not regret their decision [19].
A minority of donors nevertheless report negative
outcomes. More specifically, postdonation depressive or
anxiety symptoms have been reported in 5–23% and 6–
14% of cases, respectively [7]. Six percent to 22% report
finding the surgery/postoperative period stressful [7].
Concerns/worries include living with one kidney, com-
plications of nephrectomy, insult to own health, future
kidney problems and needing a transplant themselves in
the future, medical costs and loss of income, acquisition
of insurance and recipient outcomes [7]. Family con-
flicts, disappointment, deterioration in body image, feel-
ing ignored, a lack of appreciation, sadness or loss have
also been reported [7,20–24]. Medical complications
experienced by the recipient or donor have been shown
to be predictive of an increase in psychological symp-
toms 1 year after kidney donation [25]. One study
reported that in cases when the graft failed or the recip-
ient died, 8% experienced suicidal ideations [26]. In liv-
ing liver donors, a recent study identified five groups of
donors with varying psychosocial outcomes, of which
one (31%) reported reduced physical and socio-eco-
nomic outcomes and only limited psychological benefit
[27]. In summary, although living donation is generally
a safe procedure from a psychosocial perspective, a pro-
portion of living kidney and liver donors also experi-
ence negative consequences. Hence, transplant
professionals have a duty of care to screen, evaluate and
provide after-care for living organ donors.
In order to minimize these potential negative conse-
quences and to strive for better safety outcomes within
living donation programmes, thorough psychosocial
screening of donor candidates is required. To date,
many psychosocial screening guidelines and protocols
have been produced for specified [28–37] and unspeci-
fied liver and kidney donors [4,5,38–43]. There is, how-
ever, no broadly accepted ‘gold standard’, and the
content and process of psychosocial screening have been
shown to differ between centres and countries. Guideli-
nes published on the psychosocial evaluation of living
donors mainly originate from the United States, are
very broad and tend to list only topics of what needs to
be addressed, whilst concrete recommendations on how
screening should be performed are missing [35].
Consequently, the interpretation of these guidelines
varies substantially, leading to large differences in
screening practices and differential treatment of poten-
tial donors. Specifically, the criteria used to screen living
donors in clinical practice varies extensively [32].
Although 60% of centres seem to perform routine psy-
chosocial screening by a psychologist or psychiatrist
[44], less than 50% of them use standardized protocols
and/or validated tools [32]. Similarly, process-related
factors are under-reported in the currently available
guidelines, protocols and programme descriptions [32].
Whilst most medical guidelines provide an overview of
specific clinical or laboratory tests that should be per-
formed to describe the medical profile of a prospective
donor and their associated cut-off values, the current
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psychosocial guidelines do not recommend which tools
or tests should be used to carry out standardized and
comparable psychosocial screening of living donors.
Moreover, some European centres only perform an
in-depth psychosocial screening for unspecified (anony-
mous) donors [44].
One recent development in this field is the develop-
ment of the Living Donor Assessment Tool (LDAT)
[45]. This useful tool is the only one currently available
that outlines how screening should be conducted in
practice. The LDAT provides guidance on donation-spe-
cific issues; however, it does not integrate validated
measures on generic constructs such as depression and
anxiety which are essential components of psychosocial
screening. Furthermore, not all areas pertinent to living
donor screening are included in the LDAT, such as
health literacy and resilience.
The main aim of this paper was therefore to present
the development of the ELPAT living organ donor Psy-
chosocial Assessment Tool (EPAT) and associated pro-
cedures for implementation. We present a complete
package that can be used as an initial psychosocial
screening of living donor candidates to identify candi-
dates that require further assessment and/or support
during the donation process.
Tool development
Collaborators
This project was conducted by the members of ELPAT.
ELPAT is a European Platform on the Ethical, Legal
and Psychosocial Aspects of organ Transplantation and
is a subdivision of the European Society for Organ
Transplantation (ESOT). The core collaborators in this
project were from the working group ‘Psychosocial care
for living donors and recipients’ (n = 9). Collaborators
were psychologists (n = 7: FD, EM, LT, IM, SI and CP),
a surgeon (n = 1, HM), a psychiatrist (AL) and a trans-
plant clinical nurse specialist (n = 1, ND) working in
Belgium, Germany, the Netherlands, Portugal and the
United Kingdom.
Procedure
First, we conducted a systematic review which high-
lighted the lack of agreement regarding which criteria to
use in psychosocial screening of living kidney or liver
donors [32]. One hundred and ninety-seven unique
screening criteria were reported over all the studies
reviewed. We concluded that donor screening criteria
vary extensively across protocols. This review also high-
lighted that there was little consensus regarding the def-
inition of what ‘psychosocial’ means within the context
of donor screening. The study by Ismail et al.[46]
brought clarity to this issue by clustering the 197 psy-
chosocial screening criteria reported by Duerinckx et al.
using a rigorous concept mapping methodology. These
criteria were rated on importance in differentiating
between high- and low-risk candidates and how com-
monly the criteria were applied in current clinical prac-
tice. Analyses of these ratings resulted in six clusters of
screening criteria representing the most important and
commonly used criteria: (i) motivation and decision-
making; (ii) personal resources; (iii) psychopathology;
(iv) social resources; (v) ethical and legal factors; and
(vi) information and risk processing. These six key con-
cepts of psychosocial screening were used as a basis to
structure our tool. To translate the concepts into practi-
cal tools for implementation, we discussed how each
item could be measured, by whom and under which
conditions. For some concepts, such as depressive
symptoms, validated instruments already existed. For
donation-specific items, validated instruments were
often not available, and therefore, development of inter-
view questions was necessary.
Validated questionnaires
We searched the literature for appropriate validated
instruments and held brainstorm sessions to list poten-
tially relevant measures. Reviews in which psychometric
properties of instruments were assessed informed our
choice whether or not to include these instruments in
our own evaluation [47, 48]. An initial selection of
instruments was made per cluster. These were rated on
a standardized form by two independent raters on the
following aspects: addresses the psychosocial criterion
under investigation, previous use in the liver or kidney
transplant setting, number of items, length of time to
complete, availability in multiple languages, training
requirements to administer, availability of a handbook,
copyright and costs of use. Psychometric properties
were also evaluated as follows: sensitivity, specificity,
criterion validity, construct validity and reliability. Cri-
teria described by Vandenbroeck et al. and Kimberlin
et al. were used [49, 50]. Table 1 shows the question-
naires evaluated per domain and a summary of the pros
and cons per instrument. We considered those measures
with under 10 items as brief. A process of review and
discussion took place to come to a consensus on the
most appropriate measures (2012–2017). In order to
58 Transplant International 2018; 31: 56–70
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minimize barriers to using the tool and maximize qual-
ity, priority was given to measures that were easy to
access and implement in practice (e.g. no copyright or
fees) and those that had strong psychometric properties.
When multiple measures of equal quality were available,
the briefest measure was chosen for pragmatic reasons
and to limit burden.
During this process, we considered including a social
desirability measure in the personal resources domain.
However, consensus was achieved that it was not appro-
priate for the purpose of donor screening and that
donor candidates might question the relevance of this
type of question in this context. Social desirability can
be assessed in a second phase if deemed necessary, in
which case the Social Desirability Scale-17 (SDS-17) is
recommended. Similarly, when considering the content
of the psychopathology domain, we considered assessing
cognitive impairment. However, again we felt that this
should be assessed only upon indication, in which case
the Addenbrooke’s Cognitive Examination-III (ACE-III)
appears to be an accurate measure of this construct
[84].
Interview
In each cluster, items were generated when there was no
validated measure available. We used an iterative
approach of design, testing and redesign until consensus
was reached within the group on content and wording,
and until testing did not reveal issues warranting further
revision.
First, open-ended questions were drafted per item in
the cluster. The concept items were subsequently pilot-
tested on 12 potential living donors in one of the col-
laborating transplant centres. Overall, donor candidates
appreciated the opportunity to extensively discuss their
thoughts on donation. These ‘case-studies’ were dis-
cussed within the working group which helped refine
the wording of the questions, question order, layout
and interpretation of the answers given.
We subsequently conducted a content validity assess-
ment on the refined interview questions according to
the principles of Polit and Beck (2007). Content validity
is defined as ‘the degree to which an instrument has an
appropriate sample of items for the construct being
measured’ [85]. Typically, five or more raters are
needed in the first round of content validity evaluation.
We invited seven professionals who conduct living
donor screening in their daily practice to rate the inter-
view questions. These raters scored the individual items
according to a 4-point Likert scale ranging from not at
all relevant (1) to highly relevant (4) in the context of
psychosocial screening of donor candidates. Raters also
gave explanations for their ratings in the form of open
text. For each item, the content validity index on item
level (I-CVI) was computed as the number of experts
who gave a rating of 3 or 4, divided by the number of
experts. A target of ≥0.78 indicates good item-level con-
tent validity. Content validity index on scale-level unan-
imous agreement (S-CVI/UA) is computed as the
proportion of items for which there is unanimous
agreement on relevance among experts (S-CVI/UA).
Content validity index on scale-level average agreement
(S-CVI/Ave) is computed as an average across I-CVI’s.
Targets of ≥0.80 and ≥0.90 for the ‘universal agreement’
(S-CVI/UA) and ‘average’ (S-CVI/Ave) calculation
respectively indicate good scale-level content validity.
After the first round, the S-CVI/UA was 0.76 and the
S-CVI/Ave was 0.89. Ten out of an original set of 41
items had a suboptimal I-CVI and were revised by the
group. Some items were reformulated for enhanced
clarity and precision. All feedback from the raters was
discussed until a consensus was reached among the
working group members. The revised items were
returned to three raters (two original raters to check
revisions and one new rater), which resulted in 100%
item and scale-level content validity indices. Additional
items were added to round off the interview and check
that information was complete.
The ELPAT living organ donor Psychosocial
Assessment Tool (EPAT)
The final selection of validated questionnaires chosen
for inclusion in the tool and an overview of the admin-
istration properties are shown in Table 2. The final
semistructured interview consists of 43 items. Below we
present the chosen validated measures and summarize
the interview items per cluster as reported by Ismail
et al. [46]. To illustrate the EPAT, we present the clus-
ter ‘Psychopathology’ in its entirety in Table 3. To
accompany the tool, we developed a user manual and a
Red Flag Checklist (see Figure 1) for use during the
interview in clinical practice. Key implementation and
interpretation guidelines are highlighted below. The
complete EPAT package is available from the first and
last authors.
Motivation and decision-making
There were no appropriate measures found to assess the
concepts in this cluster. Sixteen items were included in
62 Transplant International 2018; 31: 56–70
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the interview to assess the decision-making process,
motivation, the donor–recipient relationship, pressure
to donate and ambivalence.
Personal resources
The concept ‘resilience’ was selected as it focuses on
bouncing back from stress which we felt appropriate in
the context of living donation. The Brief Resilience Scale
(BRS) [52] was included for its strong psychometric
properties and because it is the shortest of the three
resilience scales recommended by these authors [47].
Four items on stressors and coping were included in the
interview.
Psychopathology
The Patient Health Questionnaire-2 (PHQ-2) was
included to measure depressed mood and anhedonia
[59]. The purpose of the PHQ-2 is not to establish a
diagnosis or to monitor depression severity, but to serve
as an initial screen for core symptoms of depression.
Strong psychometric properties have been described,
with a sensitivity of 83% and specificity of 92% to
detect depressive symptoms [48,59,87]. The Generalized
Anxiety Disorder Questionnaire (GAD-2) was included
to measure anxiety [61]. Similar to the PHQ-2, the
purpose is to screen for symptoms of an anxiety disor-
der. Sensitivity and specificity to detect any anxiety
Figure 1 Red Flag Checklist to accompany the EPAT.
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disorder are reported to be 65% and 88%, respectively
[61]. The self-report version of the Standardized Assess-
ment of Personality – Abbreviated Scale (SAPAS-SR)
was included to measure symptoms of a personality dis-
order [65,88]. Sensitivity and specificity of detecting
personality disorders have been reported to be 83% and
80%, respectively [86]. Three items were included in the
interview to assess previous psychopathology, treatment
and memory.
Social resources
The ENRICHD Social Support Instrument (ESSI) [71]
was included to measure social support. This scale
assesses structural, instrumental and emotional sup-
port. There is evidence to support its convergent
and divergent validity [71] and criterion validity [89].
In addition, the Medical Outcomes Social Support
Scale – Tangible Support (MOSS-TS) subscale [75]
was included to measure tangible support which was
not sufficiently represented in the ESSI. There is evi-
dence for concurrent, convergent and discriminant
validity as well as reliability. Nine items were included
in the interview to assess support for donation,
employment and the financial situation of the
candidate.
Ethical and legal factors
There were no appropriate measures found to assess
concepts in this cluster. Three items were included
in the interview to assess the impact of donation on
(future) insurability and the possibility of follow-up
after donation.
Information and risk processing
A single item was included to briefly screen health liter-
acy [81,82]. Evidence suggests that this item can accu-
rately identify patients with limited or marginal health
literacy [90,91]. Five items were included in the inter-
view to assess understanding of the donation process
and associated risks.
Closing
Three items were included in the interview to assess
questions the candidate may have their commitment
and awareness of their right to withdraw at any
time.
Implementation and interpretation
This tool has been designed to assess all living donor
candidates (kidney and liver), irrespective of the donor–
recipient relationship or whether the donation is to a
specified or unspecified recipient. It should be con-
ducted after initial medical screening (e.g. blood tests
and review of past medical history) and prior to
embarking on full medical evaluation. It is essential that
the psychosocial evaluation is conducted before making
a decision about suitability to donate so that results of
the psychosocial screening are included in the decision-
making process by the multidisciplinary team.
The EPAT should be conducted in its entirety to
ensure that the screener has a complete picture of all
the issues per candidate to present to the multidisci-
plinary team and, if needed, for referral purposes.
Depending on the case and the screener, more than one
session may be necessary. Pilot testing of the entire
EPAT among three donor candidates suggested that
the tool takes 60–90 min to conduct depending on the
number and complexity of issues raised, as well as
the experience of the screener. The questionnaires
should be completed prior to the interview, (ideally in
the order presented in Table 2), and in the absence of
third parties (e.g. the potential recipient or family mem-
bers). The single item on health literacy should be
administered first so that the screener can offer support
in completing the questionnaires for candidates with
low health literacy. The proposed order of the question-
naires is intended to present less intrusive questions on
social support first, prior to more intrusive topics such
as psychopathology. The interview should be conducted
face-to-face with the donor candidate. In case of lan-
guage issues, an independent professional interpreter
should be used as opposed to a family member or
somebody brought in by the family or recipient, as this
may influence the interview process and introduce bias.
Ideally, psychosocial screening of living donors is
conducted by a mental health professional with experi-
ence in transplant care. This is in line with the current
EU directive [92] and other recommendations [93].
Should a transplant centre not have a mental health
professional as part of their interdisciplinary team, this
tool should only be used by other professionals within
the transplant team if (i) they are supervised by a men-
tal health professional on a case-by-case basis, and (ii)
they can refer to mental health services for further eval-
uation of living donor candidates if needed. Training in
use of the tool is also recommended (contact the
authors for details).
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To aid interpretation of donor candidates’ answers,
we developed a 14-item Red Flag Checklist (see Fig-
ure 1). This checklist is meant to aid the screener in
summarizing the interview and determining the next
steps. If the screener answers YES to any of the items,
this would suggest that the candidate requires further
assessment. If the screener is a mental health profes-
sional, he/she can further assess the red flags within the
same session or organize a subsequent consultation if
needed. Planning a subsequent session to further
explore these issues allows the screener time to reflect,
cross check information and consult other professionals.
If the screener is not a mental health professional, he/she
should discuss with their supervisor and, if necessary,
refer the donor for a consultation with a mental health
professional at this point.
Discussion
This project addressed the need for more concrete guid-
ance in the area of psychosocial screening of living
organ donors. Our aim was to translate the recommen-
dations of ‘what’ should be screened into practical
guidelines on ‘how’ to perform such a screening. This
resulted in the EPAT, which consists of a combination
of validated questionnaires and a semistructured inter-
view. An accompanying Red Flag Checklist and user
manual was also developed to support implementation
and interpretation of the tool. The tool is designed to
be a practical aid that can be implemented in daily clin-
ical practice for the initial exploration of psychosocial
issues among living donor candidates. It aims to iden-
tify donors who are at risk of developing negative psy-
chosocial outcomes and therefore need further
assessment and/or extra psychosocial support during the
donation process. The EPAT is likely to be particularly
useful to centres that have yet to formalize and stan-
dardize the process of psychosocial screening.
The key motives to develop the tool were to ensure
safety, quality and equality in access to living donation.
The EPAT may contribute to safety of the donation
process by assisting screeners in the psychosocial risk
analysis of living donor candidates. This in turn allows
tailored selection of intervention strategies or guidance
during the donation process. The tool contributes to
quality by way of standardization. Use of a standardized
tool ensures that no psychosocial issues are overlooked,
thus, ensuring that the procedure is comprehensive.
Moreover, the tool incorporates validated measures
which have been shown to have strong psychometric
properties to assess known constructs. The use of a
selection of validated psychological tests specifically cho-
sen for the purpose of screening of living donors has
the advantage of generating comprehensive quantitative
psychosocial data on donor candidates. The results of
these tests, as well as the results from the medical tests,
could then be integrated in an international registry
database. This would allow comparison of outcomes
and monitoring of benefits and risks for the donor over
time. Finally, the tool contributes to increasing equality
in access to donation and transplantation as the same
criteria can be applied to each candidate, so that accep-
tance of a donor candidate becomes less dependent on
setting. As Duerinckx and colleagues described, cur-
rently transplant centres use varying criteria with vary-
ing interpretations of eligibility [32].
In clinical practice, this tool still allows room for
case-by-case assessment and the clinical judgement of
the screener who should preferably be a mental health
professional. We feel that this is the standard of care,
we should strive to attain as the sensitivity of any psy-
chosocial screening will depend on the skill of the
screener. We hope that this initiative will further high-
light the clinical need for a mental health professional
in multidisciplinary transplant teams and that further
research will help generate an evidence base to support
this. However, we are also aware that in reality not all
centres have or are able to incorporate a mental health
professional into their transplant team. Therefore, with
an appropriate supervision and referral system in place,
the EPAT can also be used by other professionals.
Future research is needed to (i) translate the tool
(including the validated questionnaires) into other
languages, (ii) assess the validity and sensitivity of the
tool to predict poorer psychosocial outcomes and to
identify candidates who require additional psychosocial
support. One potential drawback to implementation
may be the length; therefore, this is potentially an area
for improvement in the next phase. Moreover, feasibil-
ity, acceptability and synergy with the medical screening
will need to be assessed.
We are aware that alternative measures could have
been chosen to be incorporated into the EPAT. How-
ever, our rigorous assessment focussed on practical fea-
sibility, whereby brevity was paramount in combination
with strong psychometric properties. Such measures
have two advantages: firstly, they limit the barriers to
implementation by limiting the time and resource bur-
den for both professional and donor candidate, and sec-
ondly, they are more likely to facilitate uptake of data
in donor registries. Another alternative tool for living
donor candidate screening is the LDAT. There is
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overlap in concepts covered by the LDAT and EPAT,
however, the EPAT additionally includes topics such as
health literacy, resilience, coping and insurability. More-
over, the use of these tools is rather different. The EPAT
includes validated measures that allow easier compar-
ison of data, outlines which questions should be posed
per domain and identifies answers that are judged to
raise red flags. Due to this standardization, the EPAT is
less likely to be influenced by experience or opinion of
the screener. In contrast, the LDAT does not stipulate
how the information should be obtained by the profes-
sional (as it is not an interview guide) but assigns a
score to the various possible answers per topic, which
in turn enables the interviewer to score the candidate as
low, moderate or high risk.
Parallel to developing the tool, we developed a user
manual that is available upon request from the first or
last author. We encourage transplant centres to use the
EPAT to assess living donor candidates and inform us
about their experiences. Moreover, we invite centres to
collaborate with us to help translate, validate and fur-
ther develop the tool.
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